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Objective: Cholesteryl ester transfer protein (CETP) plays a central role in themetabolism of high-density
lipoprotein particles. Therefore, we searched for new drugs that bind to CETP and modulate its activity.
Methods:Apreliminarypharmacophore-basedparallel screeningapproach indicated that leoligin, amajor
lignan of Edelweiss (Leontopodium alpinum Cass.), might bind to CETP. Therefore we incubated leoligin
ex vivo at different concentrations with human (n=20) and rabbit plasma (n=3), and quantiﬁed the
CETP activity by ﬂuorimeter. Probucol served as positive control. Furthermore, we dosed CETP transgenic
mice with leoligin and vehicle control by oral gavage for 7 days and measured subsequently the in vivo
modulation of CETP activity (n=5 for each treatment group).
Results: In vitro, leoligin signiﬁcantly activated CETP in human plasma at 100pM (p=0.023) and 1nM
(p=0.042), respectively, whereas leoligin concentrations of 1mM inhibited CETP activity (p=0.012). The
observed CETP activation was not species speciﬁc, as it was similar in magnitude for rabbit CETP. In vivo,
there was also a higher CETP activity after oral dosage of CETP transgenic mice with leoligin (p=0.015).
There was no short-term toxicity apparent in mice treated with leoligin.
Conclusion: CETP agonism by leoligin appears to be safe and effective, and may prove to be a useful
modality to alter high-density lipoprotein metabolism.. Introduction
Cardiovascular diseases remain to be the leading cause of death
n the developedworld. The inverse relation between high-density
ipoprotein cholesterol (HDL-C) and coronary artery disease (CAD)
as brought attention to pharmacological interventions increas-
ng plasma HDL-C [1,2]. Cholesteryl ester transfer protein (CETP)
xchanges cholesteryl esters of high-density lipoproteins (HDL)
or triglycerides of apolipoprotein B containing lipoproteins. In
he presence of CETP, large HDL2 particles lose their cholesteryl
sters and shrink in size,whereas triglyceride-rich very lowdensity
ipoproteins (VLDL) transform into cholesteryl ester rich interme-
iate density lipoproteins [2–4]. CETP, thus, plays a central role
∗ Corresponding author. Tel.: +43 316 385 80176; fax: +43 316 385 14331.
E-mail address: philipp.eller@medunigraz.at (P. Eller).
021-9150 © 2011 Elsevier Ireland Ltd.
oi:10.1016/j.atherosclerosis.2011.07.023
Open access under CC BY-NC-ND license.© 2011 Elsevier Ireland Ltd.
in lipoprotein metabolism and was pursued for several years as
a prime target for pharmacological intervention in order to treat
dyslipidemia and to prevent atherosclerosis [5–8].
Animal studies suggested that rodents lacking plasma CETP
activity or getting a CETP inhibitor held elevated HDL-C levels and
showed resistance to diet-induced atherosclerosis. Furthermore,
patients with CETP mutations tended to have increased HDL-C
plasma concentrations and less CAD [4]. Thus, the pharmacological
inhibition of CETP seemed to be a promising strategy to ﬁght CAD.
First pilot studies with CETP inhibitors showed indeed higher HDL-
C and minor low-density lipoprotein cholesterol (LDL-C) levels
without serious adverse events [5,6]. However, the ﬁrst large mul-
ticenter randomized controlled clinical trialwith theCETP inhibitor
Open access under CC BY-NC-ND license.torcetrapib was disrupted prior to schedule because of an excess of
cardiovascular and overall mortality in the active treatment group
[7]. Moreover, recent work from Vasan et al. and us revealed that
low endogenous CETP plasma levels per se were associated with
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ncreased cardiovascular and all-cause mortality in the Framing-
am, the LURIC, and the KAROLA population [9–11].
Having focussedonCETP inhibitors up tonow, there ismuch less
nformation on potential beneﬁts of a pharmacological increase of
ETP activity. Hitherto, the only known CETP-activator was probu-
ol [12]. Probucol was initially developed as an anti-oxidant to
e used in the manufacturing of tires, but was found to have
holesterol-lowering properties and thusmarketed for a number of
ears as hypolipidemic agent. A remarkable property of probucol is
ts ability to lower cholesterol in patients with homozygous famil-
al hypercholesterolemia [13]. In such patients, probucol causes
dramatic decrease in tendon and planar xanthomas, seemingly
ut of proportion to the degree of cholesterol lowering. Probucol
ncreases both the amount and the activity of CETP, and enhances
he reverse cholesterol transport [12,14]. Unfortunately, probu-
ol has severe untoward effects including prolongation of the QTc
nterval. Therefore, the substancewas retracted from themarket in
he USA and Europe, but is still in use in Japan [15].
As the role of CETP in the pathogenesis of atherosclerosis is still
pen to debate [16], we looked for new biological compounds to
lter CETP activity. Our data from in silico screenings indicated that
eoligin, the major lignan of the alpine ﬂower Edelweiss (Leon-
opodium alpinum Cass.), may bind to CETP. This natural lignan
elongs to the class of lariciresinol derivatives and was shown to
nhibit intimal hyperplasia of venous bypass grafts [17], as well as
he in vitro leukotriene biosynthesis [18]. In the present study, we
xamined the effects on blood lipids of this unique compound pro-
iding clear evidence that leoligin enhances CETP activity ex vivo
nd in vivo.
. Materials and methods
.1. Plant material, isolation, and puriﬁcation of leoligin
Leoligin (Fig. 1A) was isolated as described previously from
.3kg sub-aerial parts of Edelweiss (L. alpinum Cass.) which were
btained from Swiss horticultures [17]. The purity of leoligin
ccording to LC-DAD/MS- and NMR examination was >98%. Fur-
hermore, a voucher specimen (CH 5002) has been deposited at
he herbarium of the Institute of Pharmacy/Pharmacognosy,
niversity of Innsbruck. In addition, two further natural
erivatives of leoligin 5-methoxyleoligin (=[(2S,3R,4R)-4-(3,4-
imethoxybenzyl)-2-(3,4,5-trimethoxyphenyl)tetrahydro-
uran-3-yl]methyl-(2Z)-2-methylbut-2-en-oate and
,5′-dimethoxyleoligin (=[(2S,3R,4R)-4-(3,4,5-trimethoxybenzyl)-
-(3,4,5-trimethoxyphenyl)tetrahydro-furan-3-yl]methyl-(2Z)-2-
ethylbut-2-en-oate were isolated as described in [18] and used
or testing. The purity of both compounds was comparable to that
f leoligin.
.2. In silico screening
We performed the pharmacophore-based parallel screening
s previously described [19]. In brief, each pharmacological tar-
et is represented by one or more pharmacophore models. A
harmacophore model is an abstract representation of the lock-
nd-key hypothesis of protein–ligand interactions. It consists of
he steric and electronic features that are necessary to ensure
he optimal supramolecular interactions with a speciﬁc biological
arget and to trigger or block its biological response. A pharma-
ophore is composed of chemical features that describe types
f protein–ligand interactions such as hydrogen bonds, charged
roups, aromatic structures and hydrophobic areas. The technol-
gy to perform simultaneous, parallel screening of one compound
gainst a multitude of pharmacophore models is available as aosis 219 (2011) 109–115
Pipeline Pilot-based program protocol in Discovery Studio 2.01
(Accelrys Inc., San Diego, CA, USA). Together with this software, the
Inte:Ligand (www.inteligand.com) pharmacophore model collec-
tion of 2208 in-house generated pharmacophore models was used
for the virtual screening. The CETPmodel from the InteLigand phar-
macophore model database (www.inteligand.com/pharmdb/) and
validation studies were performed using the CATALYST software
package (Accelrys Inc., San Diego, CA, USA). Anacetrapib, a CETP
inhibitor (IC50 =13nM) that recently proceeded to phase III clinical
trials, was selected as template for ligand-based pharmacophore
elucidation [8]. Applying the feature mapping algorithm of CATA-
LYST, several models were generated by placing pharmacophoric
features on the chemical moieties of the energetically minimized
3D structure of anacetrapib. The ability of the generated models to
enrich CETP ligands among biologically inactive compounds was
validated by virtually screening them against a test set. The test set
comprised 14 CETP ligands and 32 compounds that did not show
biological activity for CETP below 100M (Suppl. Table 1). The lat-
ter were chosen as inactive ligands for model validation. The best
model was kept for virtual activity proﬁling within the InteLigand
pharmacophore model collection. The CETP model comprised a
hydrogen bond acceptor ﬁtted to the oxazolidin-2-one moiety of
anacetrapib, as well as two aromatic and two hydrophobic inter-
actions. The model retrieved 13 test set inhibitors (93%) and two
inactive compounds (6%). The enrichment of actives compared to a
random selection was measured using the enrichment factor (EF)
calculated by the following equation [19]: EF= (TP/n)/(A/N). TP is
the number of actives retrieved by the model, n is the number of
actives and inactive compounds retrieved by the model, A is the
number of actives in the test set, and N is the number of all com-
pounds in the test set. The EF determined for the CETP model was
2.85. The maximum EF for this dataset, where a model would ﬁnd
only active compounds, would have been 3.29. The high EF of this
model indicated high quality and restrictivity.
2.3. Lipidiological analyses
The studyprotocolwas approvedby theuniversity ethics review
board (# AN4143 294/4.1) and complies with the Declaration of
Helsinki. All participants gave written informed consent before the
trial and ﬁlled standardized questionnaires for baseline informa-
tion. Blood sampleswere collected from20healthy volunteers after
anovernight fast. Total plasmacholesterol, triglycerides, andHDL-C
weremeasured inwhole plasma using Roche Diagnostics commer-
cial kits (RocheDiagnostics,Mannheim,Germany). Due to the small
volume size of available plasma samples from CETP transgenic
mice, single measurements of HDL- and LDL-cholesterol for each
animal were not possible. As a surrogate, we used FPLC lipid pro-
ﬁles from pooled murine plasma samples to differentiate between
the high-density and low-density lipoprotein cholesterol fractions
in the different treatment arms. The murine plasma samples were
subjected to FPLC fractionation analysis with two tandem superose
6 columns (GEHealthcare, Vienna, Austria), as describedpreviously
[20]. CETP activity was measured using a commercial CETP activity
assay kit (BioVision, Mountain View, CA, USA). Brieﬂy, CETP activ-
ity was determined in microplates by a ﬂuorescent method using
a donor molecule containing a ﬂuorescent self-quenched neutral
lipid that is transferred to an acceptor molecule in the presence
of CETP. Three L of human plasma were used per well and the
plate was incubated for 30min at 37 ◦C. CETP-mediated transfer of
the ﬂuorescent neutral lipid to the acceptor molecule results in an
increase in ﬂuorescence which was measured with the ﬂuorime-
ter Tecan inﬁnite M200 and the appropriate software i-control 1.6
(Tecan Group, Maennedorf, Switzerland). CETP plasma levels were
determined using an enzyme-linked immunosorbent assay (ELISA)
employing a CETP-speciﬁc recombinant single-chain antibody
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Fig. 1. Chemical structure of leoligin, leoligin derivatives, and probucol, and the pharmacophore model for CETP. Leoligin (A) is a lignan, which was isolated from the
roots of Edelweiss (Leontopodium alpinum Cass.). The IUPAC name for leoligin is: [(2S,3R,4R)-4-(3,4-dimethoxybenzyl)-2-(3,4-dimethoxyphenyl)tetrahydrofuran-3-yl]methyl
(2Z)-2-methylbut-2-enoat. (B) The pharmacophore model for CETP shows in its vectorized feature consisting of two green spheres a hydrogen bond acceptor, the two
orange vectorized features represent aromatic interactions, and the two blue spheres display hydrophobic interactions. The ﬁgure was generated applying the DS Visualizer
software. There are two natural derivatives of leoligin, namely 5-methoxyleoligin (=[(2S,3R,4R)-4-(3,4-dimethoxybenzyl)-2-(3,4,5-trimethoxyphenyl)tetrahydro-furan-3-
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Gl]methyl-(2Z)-2-methylbut-2-en-oate (C), and 5,5′-dimethoxyleoligin (=[(2S,3R,4R
2Z)-2-methylbut-2-en-oate (D). Probucol (4,4′-[propane-2, 2-diylbis(thio)]bis(2,6
nﬂammatory properties. (For interpretation of the references to color in this ﬁgure
s coating antibody and an afﬁnity-puriﬁed polyclonal rabbit anti-
ETP antibody as detection antibody, respectively [21]. The TaqIB
olymorphism in the human CETP genewas determined by restric-
ion fragment length polymorphism (RFLP) analysis as well as
y real time polymerase chain (PCR) reaction with TaqMan-MGB
rimers and probes. For RFLP analysis, a 991-bp fragment of intron
of the CETP gene was ampliﬁed using the following primer pair:
′-CAG GGG TCT TTT CAT GGA CAC-3′ (forward) and 5′-CAC TTG
GC AAC CCA TAC TTG ACT-3′ (reverse). The resulting PCR-product
as digested with TaqI (New England BioLabs, Ipswich, MA, USA).
or real time analyses we used the forward primer sequence 5′-
CC CTA ACC TGG CTC AGA TC-3′, the reverse primer sequence
′-GCC AGG TAT AGG GAT TTG TGT TGT T-3′, and the TaqMan-
GB probes FAM-CCC TAA CTT GAA CCC and HEX-CCC TAA CTC
AA CCC [22]. TaqMan Real Time PCR reactionswere performed on,4,5-trimethoxybenzyl)-2-(3,4,5-trimethoxyphenyl)tetrahydro-furan-3-yl]methyl-
t-butylphenol)) (E) is a diphenolic substance with cholesterol-lowering and anti-
d, the reader is referred to the web version of the article.)
a MX4000H Multiplex Quantitative PCR System (Stratagene, Ams-
terdam, Netherlands).
2.4. Animal studies
All animals were handled in strict accordance with good ani-
mal practice as deﬁned by the Austrian Authorities and the
European Commission Directive 86/609/EEC, and all animal work
was approved by the Austrian Animal Care and Use Committee
(# BMWF-66.011/017-II/3b/2010). Animals were maintained in a
virus/antibody-free central animal facility of the InnsbruckMedical
University. CETP transgenic C57BL/6-Tg(CETP)UCTP20Pnu/J mice
expressing human CETP under the control of its own promoter and
othermajor regulatory elements, were kindly provided byMiranda
van Eck [23]. Themice were fed a standard chow diet (Ssniff, Soest,
1 osclerosis 219 (2011) 109–115
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Fig. 2. Leoligin enhances the activity of human and rabbit cholesteryl ester trans-
fer protein. (A) The activity of the cholesteryl ester transfer protein (CETP) was
determined in humanplasma after incubationwith different concentrations of leoli-
gin (closed circles) and probucol (open squares), respectively. Leoligin signiﬁcantly
increased CETP activity at concentrations of 100pM (n=20; p=0.023) and 1nM
(p=0.042). At higher leoligin concentrations of 1mM, CETP activity was signiﬁ-
cantly inhibited (p=0.012). Probucol (open squares) increased the CETP activity
at even lower concentrations of 1pM (n=20; p=0.040). (B) Leoligin (black bars)
signiﬁcantly increased rabbit CETP activity in a concentration of 100pM (n=3;
p=0.047), and inhibited rabbit CETP activity at higher concentrations of 1M(n=5;
p=0.019), and 100M (n=5; p=0.00006), respectively. Probucol (white bars) did
not alter rabbit CETP activity. Data are given asmeans± SEM. Signiﬁcant differences
were calculated by Student’s t-test for unpaired data. * indicates p-value <0.05. (C)
Leoligin-derivatives did not signiﬁcantly regulate the activity of human cholesteryl
ester transfer protein (n=10). The activity of the cholesteryl ester transfer protein12 K. Duwensee et al. / Ather
ermany). Both, diet and water were provided ad libitum. After 4
eeks of acclimatization, the CETP transgenic mice were divided
nto two treatment groups: a leoligin-treated, and a control group
ith vehicle alone. Leoligin was dissolved in a stock solution of
imethylsulfoxide (Sigma, St. Louis, MI, USA), and subsequently
iluted in 0.5% methylcellulose (Carl Roth, Karlsruhe, Germany).
he daily dosage of leoligin was 0.14mg/d. It was applied orally
nce daily using an infusion canule with a bulb end (Acuﬁrm Ernst
ratz Nadelfabrik, Dreieich, Germany) [24]. After 7 days of treat-
ent, animals were fasted for 6h and blood samples were taken
or lipidological analyses.
.5. Molecular docking
In order to gain more insight into the mechanism of action of
eoligin, it was docked into the X-ray crystal structure of CETP (Pro-
ein Data Bank entry 2obd, www.pdb.org PDB). The software GOLD
.1 (Cambridge Crystallographic Data Center – CCDC, Cambridge,
K;www.ccdc.cam.ac.uk/products/life sciences/gold/)wasused in
rder to perform these docking experiments [25]. This software
mploys a genetic algorithm that allows the prediction of possi-
le binding modes of small molecules to the ligand binding site
f a protein. GOLD creates several docking solutions which subse-
uently are ranked by scoring functions. For docking experiments,
he default parameters of GOLD were applied. The ligand binding
itewas deﬁned by choosing all four ligands (two cholesteryl esters
nd two phospholipids), and all atomswithin 10 A˚were considered
or docking. Crystallized water molecules were preserved. Leoli-
in preparation for GOLD was carried out using Corina 3.0. Driver
ptionswere set to preserve stereochemistry,write hydrogens, and
emove additional 2D info from output ﬁles.
.6. Statistical analysis
Results are presented as mean± SEM. When comparing two
roups, the Student’s t-test was performed for data with normal
istribution and the nonparametric Mann–Whitney U test was
erformed for data without normal distribution, respectively. A
-value <0.05 was considered signiﬁcant. When comparing three
roups, we performed the Kruskal–Wallis test. When signiﬁcances
ere detected, groups were compared by Mann–Whitney U test.
he level of signiﬁcancewas corrected to thenumber of groups, and
p-value <0.025 was considered signiﬁcant. All statistical analyses
ere performed using SPSS 15.1 for Windows (SPSS, Inc., Chicago,
L, USA).
. Experimental results
Edelweiss (L. alpinum Cass.) is a popular alpine plant that has
een used for centuries in folk medicine to treat indigestion, fever,
nd ‘abdominal aches’. In order to analyze the potential therapeu-
ic signiﬁcance of this plant, its phytochemical constituents were
solated, characterized and screened for potential pharmacological
argets using pharmacophore-based activity proﬁling. Our prelim-
nary in silico studies revealed a possible interaction of leoligin
Fig. 1A), the major lignan of Edelweiss, with the pharmacophore
odel for cholesteryl ester transfer protein (Fig. 1B). Here, we
peciﬁcally analyzed this interaction and found leoligin to activate
uman CETP in vitro and in vivo.
First, we determined the in vitro activity of CETP after incuba-
ion with different concentrations of leoligin and its two natural
erivatives (Fig. 1C and D). Probucol is an activator of human CETP
nd served as positive control (Fig. 1E). The clinical and biochemi-
al characteristics of the study population (n=20) are given in the
uppl. Table 2 In human plasma, leoligin signiﬁcantly increased
ETP activity by 32.3% at a concentration of 100pM (p=0.023), and(CETP) was determined in human plasma after incubation with different concen-
trations of leoligin (closed circles), 5,5′-dimethoxyleoligin (open diamonds), and
5-methoxyleoligin (open triangles), respectively. Data are given as means± SEM.by 29.0% at a concentration of 1nM (p=0.042) (Fig. 2A). Higher
leoligin doses (1mM) signiﬁcantly inhibited CETP activity to 44.8%
of control (p=0.012). The activation of CETP by leoligin was sim-
ilar in size as that observed for probucol. Probucol signiﬁcantly
K. Duwensee et al. / Atherosclerosis 219 (2011) 109–115 113
Fig. 3. Leoligin activates cholesteryl ester transfer protein in vivo. CETP transgenic
mice (n=5 in each group) were dosed orally with equal daily amounts of leoligin
(black bars), or vehicle control (white bars) for 7 days. (A) The CETP activity was
measured after these 7 days. There was a higher in vivo CETP activity in leoligin
treated mice when compared to controls (p=0.015). (B) The lipid proﬁles showed a
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Biochemical characteristics of CETP transgenicmice treatedwith leoligin andvehicle
control.
Control Leoligin p-Value
Body weight (g) 24.0 ± 1.5 23.7 ± 1.4 0.902
Cholesterol (mg/dL) 68 ± 7 76 ± 4 0.404
Triglycerides (mg/dL) 80 ± 10 92 ± 4 0.307
CETP mass (g/mL) 1.40 ± 0.10 1.22 ± 0.07 0.240
PLTP (pmol/L/h) 20.5 ± 3.7 17.5 ± 2.7 0.560
Urea (mg/dL) 53.9 ± 3.5 49.9 ± 1.2 0.418
Alanine transaminase (U/L) 30.3 ± 2.2 35.7 ± 3.1 0.321
Aspartate transaminase (U/L) 66.0 ± 7.8 80.7 ± 13.1 0.476
Leukocytes (G/L) 5.8 ± 0.2 6.3 ± 0.5 0.537
Erythrocytes (T/L) 7.7 ± 0.2 7.5 ± 0.2 0.490
Hemoglobin (g/dL) 14.6 ± 0.5 14.1 ± 0.2 0.401
Hematocrit (%) 40.1 ± 1.2 38.5 ± 0.3 0.296
MCV (fL) 52.0 ± 0.5 51.3 ± 0.7 0.492
MCH (pg) 18.9 ± 0.1 19.0 ± 0.2 0.722
anticipate whether leoligin is just a new pharmacological tool torend to lower LDL-cholesterol levels in the leoligin treated animals (closed circles),
hen compared to controls (open squares). * indicates p-value <0.05.
ncreased CETP activity in vitro at an even lower concentration
f 1pM up to 31.5% (p=0.040). The modulation of CETP by leoli-
in was not restricted to the human CETP isoform. We also tested
he interaction of leoligin with the rabbit CETP isoform. Leoligin
igniﬁcantly increased rabbit CETP activity to 146.9±6.9% of con-
rol (n=3; p=0.047) in a concentration of 100pM (p=0.047), and it
ecreased rabbit CETP activity in a higher concentration of 100M
o 53.4%±1.9% of control (n=5; p=0.00006), respectively (Fig. 2B).
hus, there was a similar pharmacological ﬁngerprint of leoligin
ith an activation of CETP activity in the nanomolar range and an
nhibition of CETP activity in the millimolar range both in human
nd in rabbit plasma. In order to prove the speciﬁcity of this interac-
ion of leoligin with CETP, we puriﬁed human CETP from plasma in
n immunosorbent microplate coated with CETP-speciﬁc recom-
inant antibodies. After several washing steps and spiking with
ifferent leoligin concentrations, CETP activity was measured and
howedagain a clear activation at concentrations of 100pMto1nM
p<0.05). We also tested the two natural leoligin derivatives 5-
ethoxyleoligin and 5,5′-dimethoxyleoligin in our experimental
etting (Fig. 1C and D). As shown in Fig. 2C, the leoligin derivatives
-methoxyleoliginand5,5′-dimethoxyleoliginwerenot effective in
nducing CETP activity, respectively (n=10 for each leoligin deriva-
ive).
Next, we tested whether leoligin activated CETP in vivo. For this
urposeweusedCETP transgenicmice. Thedailydosagesof leoligin
ere applied by oral gavage over 7 days. As shown in Fig. 3A, there
as a higher in vivo CETP activity in leoligin treated mice when
ompared to controls. Moreover, there was a trend to lower LDL-
holesterol levels in leoligin treated animals, when compared toAbbreviations: PLTP, phospholipid transfer protein;MCV,mean corpuscular volume;
MCH, mean corpuscular hemoglobin.
controls (Fig. 3B). In order to prove that the in vivo treatment with
leoliginwasboth safe andeffective,wealsomadeablood cell count,
and analyzed liver and kidney parameters after 7 days of treatment.
As shown in Table 1, there was no signiﬁcant difference in these
biochemical markers between the control and the leoligin-treated
group.
Ultimately, we performed docking experiments to characterize
the putative molecular binding mode for leoligin to CETP. In gen-
eral, CETP is a boomerang-shaped protein with a long, continuous
tunnel (Fig. 4A). Within this tunnel two cholesteryl ester and two
phospholipid molecules can bind at the same time. In the center of
this tunnel, the so-called neck, its diameter narrows. In the dock-
ing studies, leoligin bound near the neck region forming extensive
hydrophobic contacts (Fig. 4B–D).
4. Discussion
In the present study, we clearly demonstrate that leoligin,
a major lignan from the roots of Edelweiss (L. alpinum Cass.),
activated CETP both ex vivo and in vivo. This pharmacological inter-
action was not restricted to the human isoform of CETP, but was
also true for the rabbit CETP, and occurred at nanomolar concen-
trations. Beside its effectiveness, CETP agonism by leoligin seemed
safe in the short term, as there was no overt toxicity observed in
our experimental setting.
The pharamcophore model for CETP was designed using estab-
lished CETP inhibitors. While searching for CETP inhibitors, we
found a CETP activator. This paradoxical ﬁnding might indicate
that leoligin is an allosteric activator of cholesteryl ester trans-
fer at nanomolar concentrations. Moreover, it is not surprising for
the hydrophobic substance leoligin to inhibit CETP activity at mil-
limolar concentration, as it may accumulate in the hydrophobic
tunnel of CETP and thus inhibit cholesteryl ester and phospholipid
transport by CETP at excessively high concentrations.
Cholesteryl ester transfer protein antagonism has been pursued
for several years as a prime target for pharmacological interven-
tion in an effort to increase high-density lipoprotein cholesterol
and to prevent atherosclerosis. However, the clinical outcome of
these trials addressing CETP inhibition has been equivocal [26–28].
So far, the only clinically relevant CETP activator has been probucol,
which remarkably lowers cholesterol in patients with homozy-
gous familial hypercholesterolemia [29]. At themoment,we cannotstudy high-density lipoprotein metabolism or whether it may also
prove a usefulmodality to treat selected patient populations. Leoli-
gin seems to differ from probucol, as leoligin did not to increase
114 K. Duwensee et al. / Atherosclerosis 219 (2011) 109–115
Fig. 4. Proposed molecular binding mode of leoligin next to the CETP neck region. CETP (A) is a boomerang-shaped protein forming a long, hydrophobic tunnel. In the
X-ray crystal structure (B), this tunnel contains two cholesteryl ester molecules (gold). Leoligin (black) was predicted to bind in an area just between these two ligands,
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[ext to the CETP neck region. (C) Docking mode of leoligin within the hydrophobic
reen. Substituents of leoligin forming hydrophobic contacts with CETP are highlig
nteractions are indicated by yellow curves. (For interpretation of the references to
ETP mass in CETP transgenic mice, whereas probucol increases
oth human CETP plasma levels and CETP activity [12,14]. This dif-
erence may be due to genuine pharmacodynamic characteristics
f the tested drugs, but could also be caused by the completely dif-
erent experimental settings. We used a short-term dosing of CETP
ransgenic mice over 7 days and have not yet analyzed long-term
ffects of leoligin treatment in our animal model. Moreover, CETP
ransgenic mice do carry the human CETP gene under the control
f its own promoter, but can obviously not substitute for human
linical trials. Therefore, further analyses are needed to study the
ong-term effects of leoligin on CETP expression in different tissues
nd organisms.
Taken all experimental evidence together, it appears that the
linical impact of CETP modulation on atherosclerosis most likely
epends on the actual lipoprotein distribution in a given clinical
etting. Therefore, future clinical trials addressingCETPmodulation
ill have to carefully select patientswithwell characterizedplasma
ipids and lipoproteins, if they are to ﬁnd out what kind of patients,
f any, will beneﬁt from such interventions.
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